dnajc21 Antibody

What is DNAJC21 and why is it a significant research target?

DNAJC21 (DnaJ Heat Shock Protein Family (Hsp40) Member C21) is a ubiquitously expressed chaperone protein that plays a critical role in ribosomal biogenesis, specifically in the maturation of the 60S ribosomal subunit. Research interest in DNAJC21 has intensified since mutations in this gene were linked to bone marrow failure syndromes with high predisposition for myeloid malignancies, particularly Shwachman-Diamond syndrome (SDS) . Recent studies have demonstrated that DNAJC21 associates with rRNA and interacts with cofactors including PA2G4, HSPA8, and ZNF622 involved in 60S ribosomal maturation . Loss of DNAJC21 induces abnormal cell morphology, inhibits cell growth, and leads to cytopenia through impaired hematopoietic differentiation .

Which applications are most effectively supported by current DNAJC21 antibodies?

Current commercially available DNAJC21 antibodies support multiple applications with varying effectiveness:

The applications with highest reported consistency across antibodies are Western blot and immunofluorescence, with validated reactivity in human, mouse, and rat samples .

How do monoclonal and polyclonal DNAJC21 antibodies compare in research applications?

Both monoclonal (e.g., 68343-1-Ig) and polyclonal (e.g., 23411-1-AP, HPA040789) DNAJC21 antibodies are available with distinct advantages:

Monoclonal antibodies:

• Provide consistent lot-to-lot reproducibility

• Show higher specificity for single epitopes

• The mouse monoclonal 68343-1-Ig has been validated for WB (1:5000-1:50000) and IF/ICC (1:400-1:1600)

• Observe consistent 70 kDa band detection in multiple cell lines (K-562, HSC-T6, NIH/3T3)

Polyclonal antibodies:

• Offer higher sensitivity through recognition of multiple epitopes

• The rabbit polyclonal 23411-1-AP supports broader application range (WB, IHC, IF/ICC, IP)

• Greater versatility across species (human, mouse, rat)

• More suitable for detecting DNAJC21 under varying experimental conditions

Selection should be based on specific experimental needs, with polyclonals preferred for detection sensitivity and monoclonals for high specificity applications.

What are the optimal protocols for subcellular localization studies of DNAJC21?

DNAJC21 exhibits both nuclear and cytoplasmic localization, with enrichment in nucleolar regions. For optimal subcellular localization studies:

Immunofluorescence protocol:

• Fix cells with 4% paraformaldehyde (10 min, room temperature)

• Permeabilize with 0.1% Triton X-100 (5 min)

• Block with 3% BSA in PBS (30 min)

• Incubate with primary DNAJC21 antibody at 1:20-1:200 dilution (overnight, 4°C)

• Apply fluorophore-conjugated secondary antibody (1h, room temperature)

• Counterstain nuclei with DAPI

• Use nucleophosmin (NPM1) as a nucleolar marker for co-localization studies

For subcellular fractionation:

• Lyse cells in ice-cold HEPES buffer containing 0.1% NP40

• Centrifuge at 3,000 rpm to separate cytoplasmic (supernatant) and nuclear fractions

• Wash nuclear pellet three times in ice-cold HEPES with 0.1% NP40

• Extract nuclear proteins using RIPA buffer with protease/phosphatase inhibitors

• Sonicate twice (10s, 50% pulse) to release nuclear proteins

• Use TBP as control for nuclear fractions in Western blot analysis

Both approaches consistently show DNAJC21 in both compartments, with enhanced nuclear/nucleolar signals following actinomycin D treatment, suggesting active shuttling between compartments.

How should researchers optimize rRNA co-immunoprecipitation with DNAJC21 antibodies?

For effective rRNA co-immunoprecipitation with DNAJC21:

• Pre-IP preparation:

  • Generate GFP-tagged DNAJC21 constructs (or use endogenous protein with validated antibodies)

  • Prepare nuclear extracts from approximately 10^6 cells

  • Pre-clear lysates with control IgG (e.g., rabbit control IgG, monoclonal SP137)

• Immunoprecipitation:

  • Incubate cleared lysates with anti-DNAJC21 antibody (10 μl, overnight at 4°C)

  • For tagged constructs, use GFP-TRAP agarose beads (ChromTek)

  • For native protein, use Protein A Dynabeads pre-equilibrated with IP buffer

  • Perform stringent washes to reduce background

• RNA extraction and control treatments:

  • Treat immune complexes with DNase I (RNase-free) for 30 min at 37°C

  • Include RNase inhibitor (RNasein) during processing

  • For RNA specificity controls, include parallel samples treated with RNase A (25 μg/mL)

  • Extract RNA using Trizol method followed by RNeasy purification

  • Include input RNA controls from pre-IP samples

• Analysis:

  • Quantify rRNA by RT-qPCR using primers specific for various ribosomal RNA regions

  • Compare wild-type DNAJC21 with mutant forms to identify functional domains

  • Use GAPDH mRNA as normalization control

This approach has successfully demonstrated that DNAJC21 associates with rRNA, with this interaction disrupted in disease-associated mutations.

What controls are essential when using DNAJC21 antibodies for studying SDS or bone marrow failure?

When investigating DNAJC21's role in Shwachman-Diamond syndrome (SDS) or bone marrow failure, these controls are essential:

Antibody validation controls:

• Include samples from DNAJC21-null or knockdown models (cells with DNAJC21 shRNA)

• Use patient-derived cells with known DNAJC21 mutations as biological validation

• Include heterozygous parent controls for patient samples to observe dose-dependent effects

Experimental controls for functional studies:

• In actinomycin D sensitivity assays, include dose-response curves (0-5 nM range) with viability measurements at multiple timepoints (24-72h)

• For RNA analyses, normalize to multiple housekeeping genes beyond GAPDH (e.g., ACTB, B2M)

• Include small nucleolar RNAs (snoRNAs) such as SNORA63 and SNORA68 as internal controls for nuclear RNA processing

Disease-specific controls:

• Compare DNAJC21-mutated samples with other SDS subtypes (e.g., SBDS mutations)

• For hematopoietic studies, include parallel analyses of multiple lineages (myeloid, erythroid, lymphoid)

• In rescue experiments, include both wild-type DNAJC21 and disease-associated mutant forms

Cellular stress response controls:

• Measure DNA damage markers (γH2AX) alongside DNAJC21 expression

• Assess cell proliferation (e.g., EdU incorporation) and apoptosis (Annexin V) in parallel

• For nucleotide metabolism studies, analyze multiple nucleoside effects (not just thymidine)

These comprehensive controls help distinguish DNAJC21-specific effects from general cellular stress responses.

How can researchers effectively use DNAJC21 antibodies to study ribosomal biogenesis defects?

To leverage DNAJC21 antibodies for studying ribosomal biogenesis defects:

• Combined immunoprecipitation and mass spectrometry approach:

  • Perform immunoprecipitation using DNAJC21 antibodies (e.g., 23411-1-AP at 0.5-4.0 μg per 1-3 mg lysate)

  • Analyze co-precipitating proteins by mass spectrometry to identify ribosome-associated factors

  • Focus on established DNAJC21 interaction partners (PA2G4, HSPA8, ZNF622) and identify novel associations

• Ribosomal subunit fractionation analysis:

  • Separate ribosomal subunits and intermediates using sucrose gradient ultracentrifugation

  • Collect fractions and analyze DNAJC21 distribution by Western blot

  • Compare profiles between normal and DNAJC21-deficient cells to identify accumulation of specific pre-ribosomal intermediates

  • Correlate with aberrant PA2G4 localization, a marker of defective 60S export

• Nucleolar stress visualization:

  • Use immunofluorescence with DNAJC21 antibodies (1:20-1:200 dilution)

  • Co-stain with nucleolar markers (fibrillarin, nucleophosmin)

  • Quantify nucleolar morphology changes and DNAJC21 localization upon ribosomal stress induction (actinomycin D treatment)

  • Compare responses between wild-type and mutant DNAJC21 expressing cells

• Translational efficiency assessment:

  • Combine DNAJC21 immunoprecipitation with polysome profiling

  • Quantify 60S:40S subunit ratios and polysome distribution

  • Correlate findings with protein synthesis rates measured by puromycin incorporation

  • These approaches can reveal how DNAJC21 mutations affect downstream translation

These methodologies provide mechanistic insights into how DNAJC21 dysfunction leads to ribosome maturation defects in disease states.

What methodological approaches best elucidate DNAJC21's role in hematopoietic differentiation?

To investigate DNAJC21's function in hematopoietic differentiation:

• Lineage-specific analyses in model systems:

  • In zebrafish models, combine DNAJC21 antibody staining with whole-mount in situ hybridization (WISH) for hematopoietic markers:

    • myb for hematopoietic stem and progenitor cells (HSPCs)

    • lcp1 for total leukocytes

    • mpx for neutrophils

    • hbbe3 for mature erythrocytes

  • Quantify marker expression at key developmental timepoints (24, 36, 48 hpf)

• Flow cytometry with DNAJC21 co-staining:

  • Combine surface marker antibodies for hematopoietic subpopulations with intracellular DNAJC21 staining

  • Use lineage markers for:

    • HSPCs (CD34+, CD38-)

    • Myeloid progenitors (CD33+, CD34+)

    • Erythroid precursors (CD71+, CD235a+)

    • Mature neutrophils (CD16+, CD66b+)

  • Correlate DNAJC21 expression levels with differentiation stages

• Functional neutrophil response assays:

  • Challenge systems with lipopolysaccharide (LPS) for inflammatory response

  • Quantify neutrophil recruitment to inflammatory sites

  • Combine with DNAJC21 immunofluorescence to assess protein localization during activation

  • Test G-CSF responsiveness in DNAJC21-deficient models and measure neutrophil production

• Molecular rescue experiments:

  • Implement nucleoside supplementation protocols (uridine, thymidine) in DNAJC21-deficient models

  • Quantify restoration of neutrophil counts and differentiation

  • Combine with DNAJC21 antibody staining to assess protein expression changes

  • This approach has successfully demonstrated that nucleotide imbalance contributes to neutropenia in DNAJC21 deficiency

These approaches collectively reveal DNAJC21's critical role in hematopoietic differentiation and suggest therapeutic strategies for associated diseases.

How can researchers integrate DNAJC21 antibody data with nucleotide metabolism studies?

For comprehensive integration of DNAJC21 findings with nucleotide metabolism:

• Coordinate transcriptomic and metabolomic analyses:

  • Perform RNA-seq and targeted metabolomics on identical samples

  • Use DNAJC21 antibodies (e.g., 23411-1-AP) for corresponding protein expression analysis

  • Focus on nucleotide metabolism genes showing altered expression (e.g., rrm2)

  • Correlate findings with direct measurements of ribonucleotide (NTP) and deoxyribonucleotide (dNTP) pools

• DNA damage response pathway assessment:

  • Combine DNAJC21 immunofluorescence with DNA damage markers (γH2AX)

  • Measure replication stress indicators (RPA foci, 53BP1)

  • Correlate with cell cycle distribution analysis

  • This approach has revealed that DNAJC21 deficiency leads to DNA damage accumulation despite compensatory upregulation of rrm2

• Nucleoside supplementation experiments:

  • Design rescue protocols using uridine and thymidine (50-200 μM)

  • Quantify neutrophil differentiation before and after treatment

  • Measure changes in DNA damage markers and cell proliferation

  • Monitor DNAJC21 expression and localization during rescue

• Pathway integration analysis:

  • Create experimental matrices that simultaneously assess:

    • DNAJC21 protein levels (via antibody detection)

    • Ribosome profiling data

    • Nucleotide pool measurements

    • Hematopoietic differentiation markers

  • Use systems biology approaches to identify causative relationships

  • This integrative approach has revealed that DNAJC21's role extends beyond ribosome biogenesis to nucleotide metabolism regulation

These integrated approaches have uncovered a previously unrecognized link between ribosome biogenesis defects and nucleotide metabolism, providing new therapeutic targets for DNAJC21-mutant diseases.

How should researchers address discrepancies in DNAJC21 antibody detection between techniques?

When encountering inconsistencies in DNAJC21 detection across different techniques:

• Molecular weight discrepancies:

  • DNAJC21 calculated molecular weight is 58 kDa, but is commonly observed at 70 kDa

  • This discrepancy is consistent across multiple antibodies and likely represents post-translational modifications

  • Use positive controls from validated cell lines (K-562, HEK-293, HeLa) to establish proper band identification

• Subcellular localization variations:

  • DNAJC21 exhibits dynamic shuttling between cytoplasm and nucleus

  • For nuclear signal optimization:

    • Ensure proper nuclear permeabilization (0.1-0.5% Triton X-100)

    • Consider cell cycle phase (enriched nuclear signal in proliferating cells)

    • Test cellular stress conditions (actinomycin D treatment enhances nuclear localization)

  • Always include subcellular fractionation Western blots to validate IF findings

• Cross-technique validation approach:

  • For ambiguous results, implement parallel detection methods:

    • Combine Western blot (23411-1-AP, 1:2000-1:10000) with immunofluorescence (same antibody, 1:20-1:200)

    • Validate with second independent antibody (68343-1-Ig)

    • Include genetic approaches (siRNA knockdown, CRISPR knockout) as specificity controls

  • For patient samples, include heterozygous carriers as intermediary controls

• Application-specific optimization table:

These strategies help reconcile apparent discrepancies across techniques and establish reliable DNAJC21 detection protocols.

What analytical approaches help distinguish between DNAJC21 mutation effects and secondary cellular stress responses?

To differentiate primary DNAJC21 dysfunction from secondary stress responses:

• Temporal analysis framework:

  • Implement time-course experiments following DNAJC21 depletion

  • Use inducible knockdown systems (e.g., doxycycline-inducible shRNA targeting DNAJC21)

  • Measure parameters at early (24h), intermediate (48h), and late (72h) timepoints

  • Early changes likely represent direct DNAJC21 effects, while later changes may reflect adaptive or secondary responses

• Molecular signature approach:

  • Compare transcriptional profiles between:

    • DNAJC21-deficient models

    • General ribosomal stress models (low-dose actinomycin D)

    • DNA damage models (e.g., hydroxyurea treatment)

  • Identify DNAJC21-specific signature genes through differential analysis

  • Validate key signature genes at protein level with corresponding antibodies

• Genetic epistasis experiments:

  • Create compound mutant models (e.g., DNAJC21/TP53 double mutants in zebrafish)

  • Compare phenotypes between single and double mutants

  • This approach has revealed that TP53 mutation in DNAJC21-deficient background leads to myelodysplastic neoplasia-like features

  • Use antibodies against both proteins to monitor expression levels

• Pathway-specific intervention analysis:

  • Apply targeted interventions to distinct pathways:

    • Ribosome biogenesis: low-dose actinomycin D challenge

    • Nucleotide metabolism: nucleoside supplementation

    • DNA damage response: ATR/ATM inhibitors

  • Determine which interventions rescue specific DNAJC21-deficient phenotypes

  • This approach identified that pyrimidine nucleoside supplementation specifically rescues neutropenia in DNAJC21 deficiency

These approaches collectively help determine causality chains and distinguish primary molecular events from secondary cellular adaptations in DNAJC21-related pathologies.

What specialized protocols are recommended for studying DNAJC21 in rare patient samples with limited material?

For maximizing data from limited patient samples:

• Sample preservation strategy:

  • Upon collection, divide sample into multiple preservation methods:

    • Flash freeze small aliquots for protein/RNA extraction

    • Fix portion in 4% PFA for microscopy

    • Viably cryopreserve cells when possible

  • This approach ensures material for multiple analysis techniques

• Sequential extraction protocol:

  • Implement RIPA-based extraction allowing sequential isolation of:

    • RNA (using Trizol from initial lysate)

    • Protein (from organic phase)

    • DNA (from interphase)

  • This enables multi-omics from identical sample fractions

  • Use highly sensitive DNAJC21 antibodies (23411-1-AP at 1:2000 dilution) for Western blot detection

• Microscopy-based multiplexing:

  • Perform multiplexed immunofluorescence with:

    • DNAJC21 antibody (1:20-1:50 dilution)

    • Cell type markers (lineage-specific antibodies)

    • Functional readouts (proliferation, DNA damage markers)

  • Implement tyramide signal amplification for enhanced sensitivity

  • Use confocal microscopy with spectral unmixing to resolve multiple fluorophores

  • This approach provides multiparameter data from limited tissue sections

• Single-cell analysis integration:

  • When feasible, allocate portion of sample for single-cell methods:

    • scRNA-seq for transcriptome profiles

    • CyTOF/mass cytometry for protein marker panels including DNAJC21

    • Integrate with bulk sample data for comprehensive characterization

  • This approach maximizes information content from rare samples

• Patient-derived model development:

  • Establish lymphoblastoid cell lines (LCLs) from patient peripheral blood

  • Create patient-specific iPSCs when possible

  • Differentiate iPSCs into hematopoietic lineages

  • These renewable resources allow longitudinal studies with DNAJC21 antibodies

These specialized approaches have successfully generated meaningful data from limited patient materials in published DNAJC21-deficiency studies.

How can DNAJC21 antibodies contribute to understanding cancer predisposition in bone marrow failure syndromes?

DNAJC21 antibodies are valuable tools for investigating cancer predisposition mechanisms:

• Clonal evolution tracking:

  • Use DNAJC21 antibodies in combination with markers of pre-leukemic clones

  • Implement sequential immunohistochemistry on bone marrow biopsies

  • Monitor changes in DNAJC21 expression patterns during disease progression

  • This approach has revealed that DNAJC21-mutant patients have high risk for developing acute myeloid leukemia in childhood

• TP53 pathway interaction analysis:

  • Combine DNAJC21 and TP53 antibody staining in patient samples

  • Somatic TP53 mutations are frequent in SDS patients with malignant transformation

  • Zebrafish models demonstrate that tp53 mutation in dnajc21-deficient background leads to myelodysplastic features

  • Quantify co-expression patterns at single-cell resolution to identify pre-malignant populations

• DNA damage response profiling:

  • Use γH2AX and DNAJC21 co-staining to assess DNA damage accumulation

  • Quantify chromosomal instability markers (micronuclei, anaphase bridges)

  • Implement metaphase spread analysis to identify structural abnormalities

  • These approaches connect DNAJC21 deficiency to genomic instability, a hallmark of cancer predisposition

• Therapeutic vulnerability assessment:

  • Use DNAJC21 antibodies to monitor protein expression during:

    • Nucleoside supplementation treatments

    • G-CSF therapy responsiveness

    • Experimental interventions targeting nucleotide metabolism

  • Identify biomarkers predictive of treatment response or malignant transformation

  • This approach has potential for developing targeted preventative strategies for high-risk patients

These applications of DNAJC21 antibodies contribute to understanding the molecular mechanisms underlying cancer predisposition in bone marrow failure syndromes and may lead to improved surveillance and intervention strategies.

What are the recommended approaches for studying DNAJC21 post-translational modifications?

For investigating DNAJC21 post-translational modifications (PTMs):

• PTM-specific detection strategies:

  • The observed molecular weight discrepancy (calculated 58 kDa vs. observed 70 kDa) suggests significant PTMs

  • Implement immunoprecipitation with DNAJC21 antibodies (23411-1-AP, 0.5-4.0 μg)

  • Subject immunoprecipitated material to:

    • Phospho-specific antibody detection

    • Ubiquitination analysis

    • SUMOylation assessment

  • Compare patterns between normal and disease states

• Mass spectrometry characterization:

  • Perform large-scale immunoprecipitation of DNAJC21

  • Conduct tryptic digestion followed by LC-MS/MS

  • Specifically search for:

    • Phosphorylation sites (especially in the DnaJ domain)

    • Ubiquitination signatures

    • Other modifications affecting protein function

  • Validate findings with site-specific mutation approaches

• Domain-specific functional analysis:

  • Create truncation constructs targeting:

    • N-terminal DnaJ domain

    • Central region

    • C-terminal RNA-binding region

  • Express as GFP-fusion proteins

  • Assess PTM patterns with domain-specific antibodies

  • Correlate modifications with protein localization and function

• Cell cycle-dependent modification tracking:

  • Synchronize cells at different cell cycle phases

  • Analyze DNAJC21 PTM patterns by Western blot

  • Combine with immunofluorescence to assess localization changes

  • This approach may reveal regulatory mechanisms controlling DNAJC21 function during cell division

Understanding DNAJC21 PTMs will provide insights into the protein's regulation and potentially reveal novel therapeutic targets for DNAJC21-associated diseases.

How can genome editing technologies be combined with DNAJC21 antibodies to advance functional studies?

Integrating CRISPR/Cas9 genome editing with DNAJC21 antibody applications:

• Endogenous tagging strategies:

  • Use CRISPR/Cas9 to introduce small epitope tags (HA, FLAG) at the DNAJC21 locus

  • Create fluorescent protein knock-ins (GFP, mCherry) for live-cell imaging

  • Verify expression using both tag-specific and DNAJC21-specific antibodies (23411-1-AP)

  • This approach enables tracking of endogenous DNAJC21 without overexpression artifacts

• Disease-specific mutation knock-in:

  • Generate cellular models with patient-specific DNAJC21 mutations

  • Use DNAJC21 antibodies to assess protein expression, localization, and stability

  • Combine with functional assays (ribosome profiling, cell proliferation)

  • This provides isogenic systems to study mutation effects without confounding genetic background differences

• Conditional knockout systems:

  • Implement inducible CRISPR systems for temporal control of DNAJC21 depletion

  • Monitor immediate versus adaptive responses

  • Combine with rescue experiments using:

    • Wild-type DNAJC21

    • Patient-specific mutant forms

    • Domain-specific deletion constructs

  • Use DNAJC21 antibodies to validate knockout efficiency and rescue expression levels

• High-throughput phenotypic screening:

  • Create CRISPR libraries targeting DNAJC21 interaction partners

  • Use DNAJC21 antibodies as readouts for:

    • Protein localization changes

    • Expression level alterations

    • Complex formation disruption

  • Implement in disease-relevant cell types (e.g., hematopoietic progenitors)

  • This approach can identify synthetic lethal interactions and potential therapeutic targets

These integrated approaches combining genome editing with DNAJC21 antibody applications accelerate functional studies and therapeutic development for DNAJC21-associated diseases.